Allergies Clinical Development Clinical Research 
Clinical Trial Podcast
SEPTEMBER 26, 2022
Cohen has more than 30 years of healthcare experience which includes his work on clinical development. such as Senior Vice President, Global Head of Early Clinical Development and Precision Medicine, Senior Vice President, Clinical Research Strategies, Vice President and Senior Director, Medical and Scientific Services, among others.
ACRP blog
OCTOBER 10, 2024
Within the clinical trials environment specifically, AI will reduce costs and speed up the trial process, facilitating the development of more drugs and increasing access to them. MGI puts the value of this contribution to clinical development at $15 billion to $25 b illion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
VirTrial
FEBRUARY 28, 2024
Webinar Takeaways In light of recent draft guidance from the FDA on core patient-reported outcomes (PROs) in cancer trials and on dose optimization in oncology drug development – thoughtful collection and interpretation of patient experience data in oncology clinical research is becoming even more critical.
VirTrial
FEBRUARY 28, 2024
Webinar Takeaways In light of recent draft guidance from the FDA on core patient-reported outcomes (PROs) in cancer trials and on dose optimization in oncology drug development – thoughtful collection and interpretation of patient experience data in oncology clinical research is becoming even more critical.
VirTrial
FEBRUARY 28, 2024
Webinar Takeaways In light of recent draft guidance from the FDA on core patient-reported outcomes (PROs) in cancer trials and on dose optimization in oncology drug development – thoughtful collection and interpretation of patient experience data in oncology clinical research is becoming even more critical.
XTalks
SEPTEMBER 21, 2023
This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). Since 2004, the NIAID has been championing the discovery and development of the cytomegalovirus (CMV) vector used to deliver the HIV vaccine material to the immune system without causing disease. “HIV
The Pharma Data
OCTOBER 29, 2020
on clinical trial costs, throughout all study phases, across both regions. “We We are very excited about this model that seamlessly incorporates two of the most compelling and complementary international clinical research hubs for our biotech clients from early to late phase studies,” said Yvonne Lungershausen, CEO of Avance Clinical.
Expert insights. Personalized for you.
98 
Let's personalize your content